// Provide alternate content for browsers that do not support scripting // or for those that have scripting disabled. Alternate HTML content should be placed here. This content requires the Adobe Flash Player. Get Flash QVAR.com
Effect on Small Airways in Poorly Controlled Asthma:QVAR® Outdistances Fluticasone

QVAR Significantly Decreases Air Trapping (CV/VC) and Improves Small-Airway Function (FEF25%-75%) But Fluticasone Does Not3
         
  • Standard lung function tests (eg, FEV1 and PEF) do not measure small-airway obstruction1
  • Increased closing volume (CV) and air trapping reflect small-airway obstruction3,4
  • QVAR, when added to existing therapy, significantly decreased closing volume to vital capacity ratio (CV/VC),
          demonstrating reduced air trapping, and improved small-airway function3

  • The mean change in CV/VC from baseline decreased significantly more in the QVAR group than in the
          fluticasone group (P=0.0194)3
  • QVAR significantly improved prebronchodilator and postbronchodilator percent of predicted forced expiratory
          volume in 1 second (FEV1) and forced expiratory flow between 25% and 75% of vital capacity (FEF25%-75%),
          postbronchodilator residual volume, daily albuterol use, morning peak expiratory flow, and phlegm symptoms3
  • No significant improvements were seen in the fluticasone group (FEV1, FEF25%-75%, CV/VC, and daily albuterol
          use)3
QVAR® Improves Mid-Expiratory Flow FEF25%-75% vs Fluticasone3
         
box
    References:
  1. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(2):S447-S460.
  2. Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72:1016-1023.
  3. Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma. 2005;42:257-263.
  4. Zeidler M, Corren J. Hydrofluoroalkane formulations of inhaled corticosteroids for the treatment of asthma. Treat Respir Med. 2004;3(1):35-44.
080714
QVAR® is a registered trademark of IVAX Corporation, a member of the Teva Group.
©2008 Teva Specialty Pharmaceuticals LLC. This site is intended for U.S. healthcare professionals only.